Navigation Links
Filing Yaz Class Action Lawsuits Before They Expire
Date:7/18/2012

HOUSTON, July 18, 2012 /PRNewswire/ -- The attorneys at Pulaski & Middleman, LLC are actively representing women affected by the adverse side effects of the birth control drugs Yaz and Yasmin and the maker of the drugs, Bayer Pharmaceuticals. Medical malpractice lawyers are committed to protecting the legal rights of women who have been misinformed of the risks of taking these drugs.  The cutoff date for filing has not yet been determined, but the current Class Action Settlement will likely close within a year or less. Since the timeframe is unclear, it is highly recommended that women take action and file their suits now.

Bayer Pharmaceuticals recently indicated which types of cases it would agree to settle as well as what the average amount would be. More than 10,000 individuals have filed a Yaz lawsuit. The formal class action lawsuit is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation.

The most common lawsuits that have been filed are by women have suffered stroke, Deep Vein Thrombosis (DVP) or Pulmonary Embolism after taking Yaz. Recent studies have linked drospirenone, the chemical present in the birth control drugs, to blood clots that can cause these conditions to occur. The FDA recently released a study, which followed more than 825,000 women taking oral contraceptives and found that women taking Yaz face up to a 74% increased risk of developing blood clots, DVT and pulmonary embolism.

The law office of Pulaski & Middleman, LLC urges women who have experienced these life-threatening injuries to contact an experienced personal injury lawyer and investigate your rights now. The window of time to claim your injury is small as it took Bayer Pharmaceuticals 4 years to open up the settlements.

Contact the experienced Yaz attorneys at Pulaski & Middleman, LLC today if you or a loved one has experienced the harmful effects of the birth control drug. Contact toll free at 1-800-BAD-DRUG.


'/>"/>
SOURCE Pulaski & Middleman, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
2. Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf
3. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
4. Attorneys for Class of Female VPs and SVPs Employed by PR Giant MSLGroup Clarify Companys Inaccurate Description of Federal Courts Recent Certification Ruling
5. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
6. Sanford Wittels & Heisler Files $100 Million Gender Discrimination Class Action In Southern District Of New York
7. Boston Scientific Completes Patient Enrollment in PREVAIL Study for First-in-Class WATCHMAN Device
8. Frost & Sullivan: Launch of New Classes of Oral Antidiabetic Drugs by 2014 will Uplift Prospects for the European Diabetes Therapeutics Market
9. Faruqi & Faruqi, LLP Notifies Investors of June 4, 2012 Lead Plaintiff Deadline for the Class Action Filed Against Chelsea Therapeutics International
10. Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
11. eCardios CEO to Speak During "Act at the Speed of Opportunity" Event Presented by Comcast Business Class and Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- GenomeDx Biosciences today announced that six abstracts featuring Decipher ... Classifier tests will be presented at the 32 nd ... March 24 to 28, 2017 in London, ... Europe,s largest urological event showcasing the ... The abstract titled "Muscle invasive bladder cancer: ...
(Date:3/24/2017)... GENEVA , March 24, 2017 ... efforts to develop sutezolid as effective response to infectious ... TB Alliance and the Medicines Patent Pool (MPP) announced ... an antibiotic drug candidate which demonstrated encouraging results in ... sutezolid in combination with other TB drugs and follows ...
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... Procedure By Technique, Repair Procedure By Technique, By Region, By Country ... ... to grow at a CAGR of 13.35% during 2016-2021 ... aging population, growth in population with heart disease and rising advances ...
Breaking Medicine Technology:
(Date:3/24/2017)... Maryland (PRWEB) , ... March 24, 2017 , ... ... is the first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I ... their caregivers during what is often a very difficult and challenging time.” , ...
(Date:3/24/2017)... ... ... “End Time GPS”: a dauntless and enlightened study of the second-coming of Christ, ... of published author, Wesley Gerboth, a World War II veteran, with a highly-regarded reputation ... age ninety-one, he shares the Wisdom God bestowed upon him in this publication. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The ... about real people of God in congregations across the United States. “The ... minister ordained in 1964 who has served congregations in seven states throughout his ...
(Date:3/23/2017)... ... March 23, 2017 , ... In 2016 the World Health ... there could be four million Zika-related cases in the Americas within the next year. ... US cases reported per year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and ...
(Date:3/23/2017)... ... ... The physicians of KSF Orthopaedic Center PA are proud to announce the opening ... at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 inside the new ... in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) with an even ...
Breaking Medicine News(10 mins):